ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from ...
Amylin gets full custody of Byetta; Lilly will transfer Byetta commercial work to Amylin by Nov. 30 in the U.S. Lilly's Byetta and Bydureon operations in Europe will move market-by-market over 2012 ...
Now, I will provide a commercial update starting with BYETTA and then moving on to SYMLIN. BYETTA; is the first and only FDA approved incretin mimetic, a new class of drugs that mimics the action of ...
Minor Label Changes and Approval of Once Weekly Version of Drug Are Anticipated The increasing incidence of obesity has ushered in a ripe market for type 2 diabetes drugs. The commercial landscape is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results